Last Updated: November 16, 2026

SOHONOS Drug Patent Profile

« Back to Dashboard


Which patents cover Sohonos, and what generic alternatives are available?

Sohonos is a drug marketed by Ipsen and is included in one NDA. There are nine patents protecting this drug.

The generic ingredient in SOHONOS is palovarotene. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the palovarotene profile page.

DrugPatentWatch® Generic Entry Outlook for Sohonos

Sohonos will be eligible for patent challenges on August 16, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 16, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for SOHONOS?
  • What are the global sales for SOHONOS?
  • What is Average Wholesale Price for SOHONOS?
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SOHONOS
Generic Entry Date for SOHONOS*:
Constraining patent/regulatory exclusivity:

FOR THE REDUCTION IN VOLUME OF NEW HETEROTOPIC OSSIFICATION IN ADULTS AND PEDIATRIC PATIENTS AGED 8 YEARS AND OLDER FOR FEMALES AND 10 YEARS AND OLDER FOR MALES WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)

NDA:
Dosage:

CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for SOHONOS
Drug ClassRetinoid

US Patents and Regulatory Information for SOHONOS

SOHONOS is protected by nine US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SOHONOS is ⤷  Start Trial.

This potential generic entry date is based on FOR THE REDUCTION IN VOLUME OF NEW HETEROTOPIC OSSIFICATION IN ADULTS AND PEDIATRIC PATIENTS AGED 8 YEARS AND OLDER FOR FEMALES AND 10 YEARS AND OLDER FOR MALES WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP).

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-004 Aug 16, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-003 Aug 16, 2023 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-005 Aug 16, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-005 Aug 16, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-005 Aug 16, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Ipsen SOHONOS palovarotene CAPSULE;ORAL 215559-005 Aug 16, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for SOHONOS

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Ipsen Pharma Sohonos palovarotene EMEA/H/C/004867Treatment of fibrodysplasia ossificans progressiva. Refused no no yes 2023-07-17
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for SOHONOS

See the table below for patents covering SOHONOS around the world.

Country Patent Number Title Estimated Expiration
Australia 2011296080 Composition and method for muscle repair and regeneration ⤷  Start Trial
Brazil 112013004685 composição e método para reparação e regeneração muscular ⤷  Start Trial
Canada 2809374 COMPOSITION ET METHODE DE REPARATION ET DE REGENERATION MUSCULAIRES (COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION) ⤷  Start Trial
Chile 2013000580 Metodo de regeneracion o reparacion muscular que comprende administrar un antagonista del receptor de acido retinoico gama (rary); metodo para la induccion o estimulacion de diferenciacion miogenica de celulas madre; composicion que comprende celulas madre mesenquimales; composicion farmaceutica; kit. ⤷  Start Trial
China 103200937 用于肌肉修复和再生的组合物和方法 (Composition and method for muscle repair and regeneration) ⤷  Start Trial
China 111773213 用于肌肉修复和再生的组合物和方法 (COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration
DrugChatter Q&A for SOHONOS

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.